Clinical trials: CYP2D6 Polymorphism
CYP2D6 Polymorphism
Effects of Isotretinoin on CYP2D6 Activity
Specific Aim: To investigate if isotretinoin (13-cis-retinoic acid) administration decreases CYP2D6 activity in adolescent patients.
- Trial name
- NCT03076021
- Testing
- Isotretinoin, dextromethorphan
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Washington
Cytochrome P450 2D6 Ultra-rapid Metabolism
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk
The purpose of this study is to determine if non-invasive salivary genetic screening of breastfeeding mothers taking codeine will allow for the successful identification of mother-infant pairs susceptible to adverse events and to…
- Trial name
- NCT01050400
- Testing
- Cytochrome P450 2D6 (CYP2D6) genetic screening.
- Where
- Canada
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Kidney Diseases
Chinese Herb Nephropathy Epidemiology and Association With CYP2D6, CYP2C19, PXR, or MDR1 Polymorphism
1. Chinese herb nephropathy (CHN), a kind of kidney failure caused by Chinese herbs, may be related to the a component called aristolochic acid (AA). 2.
- Trial name
- NCT01503645
- Where
- 2 sites in Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
CYP2D6 Polymorphism
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
This is a multicenter, randomized, open-label, parallel, active-controlled superiority clinical study conducted in early premenopausal estrogen-receptor positive breast cancer patients with CYP2D6*10 mutations.
- Trial name
- STEP (NCT03137368)
- Testing
- Exemestane Tablets, ovarian function suppression/ablation, CYP2D6*10 gene test
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Late Onset Alzheimer Disease
Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms
Pharmacological treatment of AD is currently based on cholinesterase inhibitors (ChEI) and memantine, which have been shown to lead to modest, although effective, clinical benefits.
- Trial name
- NCT03349320
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais